Sidika Genc, Ali Taghizadehghalehjoughi, Esmanur Nigde, Kübra Karabulut, Yunus Emre Aydin, Özlem Utme, Rafig Gurbanov
Neuro-Cell Molecular Research - 2025;2(3):95-101
This study aimed to evaluate the neuroprotective effects of Xanthohumol (XAN), on Parkinson's disease and an in vitro model by focusing on PPAR-gamma and oxidative stress. To establish a Parkinson's Disease (PD) model, SH-SY5Y cells were exposed to 200 µM 6-OHDA for 15 minutes. The SH-SY5Y cells were treated with different concentrations of XAN (50, 100, and 200 µg/mL). At the end of the experiment, cytotoxicity and Oxidative stress were assessed using the MTT assay, the total antioxidant capacity (TAC) and total oxidant status (TOS) assays, and the PPAR-gamma assay. These results suggest that specific doses of XAN may have neuroprotective effects with potential relevance for the treatment of neurodegenerative diseases. The Parkinson's control group shows a decrease in cell viability of up to 50% in SH-SY5Y cells compared with the control group. XAN prevented 6-OHDA-induced apoptosis and increased cell viability in a dose-dependent manner. TAC and TOS analyses showed that 100 and 200 µg/mL XAN more effectively increased TAC capacity by 60% but caused a 30% decrease in TOS. In contrast, elevated PPAR-gamma levels were measured in correlation with the MTT result. XAN results indicate that it may be part of the treatment strategy for Parkinson's disease.
